Tags

Type your tag names separated by a space and hit enter

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Expert Rev Neurother. 2013 Feb; 13(3 Suppl 1):15-9.ER

Abstract

Sativex® (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain), a cannabinoid oromucosal spray containing a 1:1 ratio of 9-δ-tetrahydrocannabinol and cannabidiol, has been licensed in Germany since July 2011 as add-on therapy for moderate-to-severe multiple sclerosis (MS) treatment-resistant spasticity symptoms. The 'MOVE 2' study evaluated clinical outcomes, treatment satisfaction, quality of life (QoL) and provision of care in MS patients with spasticity receiving Sativex in everyday clinical practice. Data from 300 patients were collected from 42 specialized MS centers across Germany and were available for this analysis. Assessments, including the MS spasticity 0-10 numerical rating scale, modified Ashworth scale, patients' and physicians' clinical impressions, and QoL scales were rated at baseline and at 1 and 3 months after starting treatment with Sativex. Sativex provided relief of MS-related spasticity in the majority of patients who were previously resistant to treatment. In addition, clear improvements were noted in MS spasticity-associated symptoms (e.g., sleep quality, bladder function and mobility), activities of daily living and QoL. Sativex was generally well tolerated. The majority of patients (84%) reported no adverse events, and there was only a limited risk of serious adverse reactions. Furthermore, based on data from Sativex clinical trials, a Markov model-based analysis has shown that Sativex is a cost-effective treatment option for patients with MS spasticity in Germany.

Authors+Show Affiliations

Neurological Rehabilitation Center Quellenhof, Kuranlagenallee 2, 75323 Bad Wildbad, Germany. peter.flachenecker@sana.de

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23369055

Citation

Flachenecker, Peter. "A New Multiple Sclerosis Spasticity Treatment Option: Effect in Everyday Clinical Practice and Cost-effectiveness in Germany." Expert Review of Neurotherapeutics, vol. 13, no. 3 Suppl 1, 2013, pp. 15-9.
Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev Neurother. 2013;13(3 Suppl 1):15-9.
Flachenecker, P. (2013). A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Review of Neurotherapeutics, 13(3 Suppl 1), 15-9. https://doi.org/10.1586/ern.13.1
Flachenecker P. A New Multiple Sclerosis Spasticity Treatment Option: Effect in Everyday Clinical Practice and Cost-effectiveness in Germany. Expert Rev Neurother. 2013;13(3 Suppl 1):15-9. PubMed PMID: 23369055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. A1 - Flachenecker,Peter, PY - 2013/2/2/entrez PY - 2013/2/13/pubmed PY - 2013/8/22/medline SP - 15 EP - 9 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 13 IS - 3 Suppl 1 N2 - Sativex® (GW Pharmaceuticals PLC, Porton Down, UK; Laboratorios Almirall, SA, Barcelona, Spain), a cannabinoid oromucosal spray containing a 1:1 ratio of 9-δ-tetrahydrocannabinol and cannabidiol, has been licensed in Germany since July 2011 as add-on therapy for moderate-to-severe multiple sclerosis (MS) treatment-resistant spasticity symptoms. The 'MOVE 2' study evaluated clinical outcomes, treatment satisfaction, quality of life (QoL) and provision of care in MS patients with spasticity receiving Sativex in everyday clinical practice. Data from 300 patients were collected from 42 specialized MS centers across Germany and were available for this analysis. Assessments, including the MS spasticity 0-10 numerical rating scale, modified Ashworth scale, patients' and physicians' clinical impressions, and QoL scales were rated at baseline and at 1 and 3 months after starting treatment with Sativex. Sativex provided relief of MS-related spasticity in the majority of patients who were previously resistant to treatment. In addition, clear improvements were noted in MS spasticity-associated symptoms (e.g., sleep quality, bladder function and mobility), activities of daily living and QoL. Sativex was generally well tolerated. The majority of patients (84%) reported no adverse events, and there was only a limited risk of serious adverse reactions. Furthermore, based on data from Sativex clinical trials, a Markov model-based analysis has shown that Sativex is a cost-effective treatment option for patients with MS spasticity in Germany. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/23369055/A_new_multiple_sclerosis_spasticity_treatment_option:_effect_in_everyday_clinical_practice_and_cost_effectiveness_in_Germany_ L2 - http://www.tandfonline.com/doi/full/10.1586/ern.13.1 DB - PRIME DP - Unbound Medicine ER -